Arca
Skip to content
Tools
Tools

CSF2RA, CSF2RB: Granulocyte-macrophage colony-stimulating factor receptor

Complex in Homo sapiens that 2 drugs act on.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2

Who is on it, and how far along

Every drug ChEMBL records acting on CSF2RA, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Antibody 1
  • Protein or peptide 1

Approved1

  • Sargramostim

Phase 30

    Phase 21

    • Mavrilimumab

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      SargramostimApprovedBayerProtein or peptideAgonistGranulocyte-macrophage colony-stimulating factor receptor agonist75
      MavrilimumabPhase 2MedImmune LLCAntibodyAntagonistGranulocyte-macrophage colony-stimulating factor receptor antagonist0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
      WOKVAC Vaccine to Prevent Brain Metastases in Metastatic HER2 Positive Breast Cancer, SHIELD TrialSargramostimPhase 2Not yet recruitingUniversity of WashingtonNov 19, 2026
      Naxitamab Enabled Transplant-Free Study in High-Risk NeuroblastomaSargramostimPhase 2RecruitingGiselle ShollerNov 12, 2026
      Labyrinthin Vaccination in Veterans With Lung AdenocarcinomaSargramostimPhase 2Not yet recruitingVA Office of Research and DevelopmentOct 6, 2026
      Hypofractionated Radiotherapy Plus GM-CSF, Pomalidomide and Glofitamab for Newly Diagnosed PCNS-DLBCLSargramostimPhase 2RecruitingThe First Affiliated Hospital of Xiamen UniversityAug 6, 2026
      A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer BurdenSargramostimPhase 2RecruitingUniversity of WashingtonJul 23, 2026
      Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5SargramostimPhase 2RecruitingShaare Zedek Medical CenterApr 17, 2026
      Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten WorseSargramostimPhase 1 / Phase 2RecruitingNational Cancer Institute (NCI)Feb 27, 2026
      DC/MM Fusion Vaccine With BCMA CAR-T in R/R MMSargramostimPhase 1RecruitingDavid AviganJan 29, 2026

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2364169, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.